Minnesota Oncology

Melanoma News

Viagra Associated with Increased Risk of Melanoma (April 18, 2014)

Men who take by Viagra (sildenafil) are 84 percent more likely to develop melanoma than men who do not, according to the results of a study published in JAMA Internal Medicine. Melanoma is a potentially fatal type of skin cancer that begins in the melanocytes,... Continue Reading

T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma (March 28, 2014)

The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a study presented at the 2014 Society of Surgical Oncology... Continue Reading

Nivolumab Produces Durable Responses in Advanced Melanoma (March 14, 2014)

Nivolumab, an investigational, anti–PD-1 drug, produced durable responses in patients with advanced melanoma, according to the results of a study published in the Journal of Clinical Oncology. Of the more than one million new diagnoses of skin cancer... Continue Reading

FDA Approves Mekinist in Combination with Tafinlar for Advanced Melanoma (January 24, 2014)

The U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) in combination with Tafinlar® (dabrafenib) to treat patients with advanced melanoma. Of the more than one million new diagnoses of skin cancer each year, roughly 76,000... Continue Reading

Yervoy Shows Long-Term Survival Advantage in Advanced Melanoma (October 23, 2013)

Patients with advanced melanoma have lived as long as ten years when treated with the immunologic therapy Yervoy® (ipilimumab), according to pooled data presented at the ESMO 2013 Congress of the European Society for Medical Oncology in Amsterdam. Of... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Tafinlar Shows Promise in BRAF-600E/K Mutant Metastatic Melanoma (August 28, 2013)

The targeted agent Tafinlar® (dabrafenib) produced a high response rate in patients with metastatic melanoma with a BRAF-V600E mutation, according to the results of a study published in the Journal of Clinical Oncology. Of the more than one million new... Continue Reading

Melanoma More Deadly in Young White Men than Women (August 12, 2013)

Adolescent and young white men with melanoma are more than 50 percent more likely than their female counterparts to die from the disease, according to the results of a study published in JAMA Dermatology.[1] Melanoma is a deadly type of skin cancer that... Continue Reading

Immunotherapy Combination Promising for Metastatic Melanoma (June 14, 2013)

For people with metastatic melanoma, treatment with a combination of Yervoy® (ipilimumab) and Leukine® (sargramostim; GM-CSF) may result in better overall survival than treatment with Yervoy alone. These results, from a Phase II clinical trial, were... Continue Reading

Intermittent Zelboraf Treatment in Patients with Melanoma May Prevent Resistance to the Drug (May 22, 2013)

Tumors resistant to Zelboraf® (vemurafenib) in patients with melanoma showed reduced growth after treatment was stopped. What’s more—animal models have shown that drug resistance was prevented by intermittent treatment. These results were presented... Continue Reading

Latest Melanoma News By Stage


Recurrent Melanoma

T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma (March 28, 2014)

The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a study presented at the 2014 Society of Surgical Oncology... Continue Reading

Nivolumab Produces Durable Responses in Advanced Melanoma (March 14, 2014)

Nivolumab, an investigational, anti–PD-1 drug, produced durable responses in patients with advanced melanoma, according to the results of a study published in the Journal of Clinical Oncology. Of the more than one million new diagnoses of skin cancer... Continue Reading

FDA Approves Mekinist in Combination with Tafinlar for Advanced Melanoma (January 24, 2014)

The U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) in combination with Tafinlar® (dabrafenib) to treat patients with advanced melanoma. Of the more than one million new diagnoses of skin cancer each year, roughly 76,000... Continue Reading

Yervoy Shows Long-Term Survival Advantage in Advanced Melanoma (October 23, 2013)

Patients with advanced melanoma have lived as long as ten years when treated with the immunologic therapy Yervoy® (ipilimumab), according to pooled data presented at the ESMO 2013 Congress of the European Society for Medical Oncology in Amsterdam. Of... Continue Reading

Tafinlar Shows Promise in BRAF-600E/K Mutant Metastatic Melanoma (August 28, 2013)

The targeted agent Tafinlar® (dabrafenib) produced a high response rate in patients with metastatic melanoma with a BRAF-V600E mutation, according to the results of a study published in the Journal of Clinical Oncology. Of the more than one million new... Continue Reading

More Recurrent Melanoma

Screening/Prevention Melanoma

Viagra Associated with Increased Risk of Melanoma (April 18, 2014)

Men who take by Viagra (sildenafil) are 84 percent more likely to develop melanoma than men who do not, according to the results of a study published in JAMA Internal Medicine. Melanoma is a potentially fatal type of skin cancer that begins in the melanocytes,... Continue Reading

Aspirin Reduces Risk of Melanoma in Women (March 20, 2013)

Women who regularly take aspirin have a reduced risk of developing melanoma, according to the results of a study published in Cancer.[1] What’s more—the longer they take the aspirin, the lower the risk. Of the more than one million new diagnoses of... Continue Reading

Lymphoma Patients and Transplant Recipients at Higher Risk of Melanoma (October 11, 2012)

Individuals with lymphoma or those who have undergone organ transplants are far more likely than the average person to develop—and die from—melanoma, according to the results of a review published in Mayo Clinic Proceedings. Melanoma is a potentially... Continue Reading

Number of Cancer Survivors Will Grow to 18 Million by 2022 (June 25, 2012)

There will be nearly 18 million cancer survivors in the United States by 2022, according to a report by the American Cancer Society and the National Cancer Institute: Cancer Treatment & Survivorship Facts & Figures[1] and an accompanying journal... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

More Screening/Prevention Melanoma

Stage III Melanoma

T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma (March 28, 2014)

The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a study presented at the 2014 Society of Surgical Oncology... Continue Reading

Yervoy Shows Long-Term Survival Advantage in Advanced Melanoma (October 23, 2013)

Patients with advanced melanoma have lived as long as ten years when treated with the immunologic therapy Yervoy® (ipilimumab), according to pooled data presented at the ESMO 2013 Congress of the European Society for Medical Oncology in Amsterdam. Of... Continue Reading

Melanoma More Deadly in Young White Men than Women (August 12, 2013)

Adolescent and young white men with melanoma are more than 50 percent more likely than their female counterparts to die from the disease, according to the results of a study published in JAMA Dermatology.[1] Melanoma is a deadly type of skin cancer that... Continue Reading

Intermittent Zelboraf Treatment in Patients with Melanoma May Prevent Resistance to the Drug (May 22, 2013)

Tumors resistant to Zelboraf® (vemurafenib) in patients with melanoma showed reduced growth after treatment was stopped. What’s more—animal models have shown that drug resistance was prevented by intermittent treatment. These results were presented... Continue Reading

Adjuvant Radiotherapy for the Management of High-Risk Malignant Melanoma (September 24, 2012)

Adjuvant radiotherapy significantly improved regional lymphatic control for high-risk patients after therapeutic lymphadenectomy for metastatic melanoma, according to the results of a study published in the Lancet Oncology. Of the more than one million... Continue Reading

More Stage III Melanoma

Stage IV Melanoma

T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma (March 28, 2014)

The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a study presented at the 2014 Society of Surgical Oncology... Continue Reading

Nivolumab Produces Durable Responses in Advanced Melanoma (March 14, 2014)

Nivolumab, an investigational, anti–PD-1 drug, produced durable responses in patients with advanced melanoma, according to the results of a study published in the Journal of Clinical Oncology. Of the more than one million new diagnoses of skin cancer... Continue Reading

FDA Approves Mekinist in Combination with Tafinlar for Advanced Melanoma (January 24, 2014)

The U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) in combination with Tafinlar® (dabrafenib) to treat patients with advanced melanoma. Of the more than one million new diagnoses of skin cancer each year, roughly 76,000... Continue Reading

Yervoy Shows Long-Term Survival Advantage in Advanced Melanoma (October 23, 2013)

Patients with advanced melanoma have lived as long as ten years when treated with the immunologic therapy Yervoy® (ipilimumab), according to pooled data presented at the ESMO 2013 Congress of the European Society for Medical Oncology in Amsterdam. Of... Continue Reading

Tafinlar Shows Promise in BRAF-600E/K Mutant Metastatic Melanoma (August 28, 2013)

The targeted agent Tafinlar® (dabrafenib) produced a high response rate in patients with metastatic melanoma with a BRAF-V600E mutation, according to the results of a study published in the Journal of Clinical Oncology. Of the more than one million new... Continue Reading

More Stage IV Melanoma

Stages I-II Melanoma

Melanoma More Deadly in Young White Men than Women (August 12, 2013)

Adolescent and young white men with melanoma are more than 50 percent more likely than their female counterparts to die from the disease, according to the results of a study published in JAMA Dermatology.[1] Melanoma is a deadly type of skin cancer that... Continue Reading

Lymphoseek Approved for Detecting Lymph Nodes in Breast Cancer and Melanoma (April 10, 2013)

The U.S. Food and Drug Administration (FDA) has approved Lymphoseek® (technetium Tc 99m tilmanocept) Injection, a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing... Continue Reading

Women More Likely to Survive Melanoma Than Men (May 16, 2012)

Women are 30 percent more likely to survive melanoma than men, according to the results of a study published in the Journal of Clinical Oncology.[1] Melanoma is a deadly type of skin cancer that arises from melanocytes, which are cells located in the... Continue Reading

Sentinel Node Biopsy Safe and Effective for Melanomas on Head and Neck (August 10, 2011)

Although the head and neck region is complex and delicate, sentinel lymph node biopsy for melanomas of the head or neck appears to be safe and effective. These results were published in Cancer. Skin cancer is the most commonly diagnosed cancer in the... Continue Reading

Wealthy Women at Higher Risk of Melanoma (April 6, 2011)

It appears that wealthier White women may be at a higher risk of melanoma than less affluent women. These findings were recently published in the Archives of Dermatology. Melanoma is the most deadly type of skin cancer. Each year in the United States,... Continue Reading

More Stages I-II Melanoma